Dose-finding study with bopindolol in arterial hypertension.

Area of Science:

• Cardiology
• Pharmacology

Background:

• Hypertension management requires effective and well-tolerated antihypertensive medications.
• Beta-blockers are a cornerstone of hypertension therapy.
• Bopindolol is a novel beta-blocker with a long duration of action.

Purpose of the Study:

• To determine the optimal dosage of bopindolol for treating mild to moderate hypertension.
• To compare the efficacy and tolerance of bopindolol with atenolol in a once-daily regimen.

Main Methods:

• A multicentric, double-blind study involving 257 hypertensive outpatients.
• Patients were randomized to bopindolol (1 mg or 2 mg) or atenolol (50 mg or 100 mg) after a placebo period.
• Dosages were doubled if diastolic blood pressure remained above 90 mm Hg; patients were followed for 12 months.

Main Results:

• All treatment groups showed significant blood pressure reduction compared to placebo.
• No significant differences in blood pressure were observed between bopindolol and atenolol groups at 4 weeks, 8 weeks, or 12 months.
• Bopindolol was equally well-tolerated as atenolol, with a lower incidence of bradycardia.

Conclusions:

• Bopindolol, particularly at 1 mg daily, is an effective and safe antihypertensive treatment for mild to moderate hypertension.
• Bopindolol offers a comparable side effect profile to atenolol, with the added benefit of reduced bradycardia.
• Bopindolol represents a valuable therapeutic option in hypertension management.